CL2015002603A1 - Anticuerpos humanos contragrem1. - Google Patents

Anticuerpos humanos contragrem1.

Info

Publication number
CL2015002603A1
CL2015002603A1 CL2015002603A CL2015002603A CL2015002603A1 CL 2015002603 A1 CL2015002603 A1 CL 2015002603A1 CL 2015002603 A CL2015002603 A CL 2015002603A CL 2015002603 A CL2015002603 A CL 2015002603A CL 2015002603 A1 CL2015002603 A1 CL 2015002603A1
Authority
CL
Chile
Prior art keywords
grem1
antibodies
human antibodies
treat
modes
Prior art date
Application number
CL2015002603A
Other languages
English (en)
Spanish (es)
Inventor
Lori C Morton
Aris Economides
Vincent J Idone
Original Assignee
Regeneron Phamarceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Phamarceuticals Inc filed Critical Regeneron Phamarceuticals Inc
Publication of CL2015002603A1 publication Critical patent/CL2015002603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2015002603A 2013-03-14 2015-09-11 Anticuerpos humanos contragrem1. CL2015002603A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782874P 2013-03-14 2013-03-14
US201361883218P 2013-09-27 2013-09-27

Publications (1)

Publication Number Publication Date
CL2015002603A1 true CL2015002603A1 (es) 2016-03-04

Family

ID=50390267

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002603A CL2015002603A1 (es) 2013-03-14 2015-09-11 Anticuerpos humanos contragrem1.

Country Status (18)

Country Link
US (3) US10377817B2 (enExample)
EP (1) EP2970448B1 (enExample)
JP (2) JP6581075B2 (enExample)
KR (1) KR20150129718A (enExample)
CN (1) CN105189548A (enExample)
AU (1) AU2014241442B2 (enExample)
BR (1) BR112015021979A2 (enExample)
CA (1) CA2904644C (enExample)
CL (1) CL2015002603A1 (enExample)
EA (1) EA201591762A1 (enExample)
ES (1) ES2898620T3 (enExample)
HK (1) HK1220469A1 (enExample)
IL (1) IL240769A0 (enExample)
MX (1) MX369574B (enExample)
PH (1) PH12015501865A1 (enExample)
SG (2) SG10201707518YA (enExample)
WO (1) WO2014159010A1 (enExample)
ZA (1) ZA201506113B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339063B2 (ja) * 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
MX369574B (es) 2013-03-14 2019-11-13 Regeneron Pharma Anticuerpos humanos contra grem1.
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN106399316B (zh) * 2016-08-26 2019-03-01 西安交通大学第一附属医院 用于识别Gremlin-1的核酸适配子及其应用
EP3504238A1 (en) * 2016-08-29 2019-07-03 Regeneron Pharmaceuticals, Inc. Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018112334A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CA3055305A1 (en) 2017-03-22 2018-09-27 Bluefin Biomedicine, Inc. Anti-tmeff1 antibodies and antibody drug conjugates
WO2018175924A1 (en) * 2017-03-24 2018-09-27 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
GB201802486D0 (en) * 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
JP7565219B2 (ja) 2018-06-18 2024-10-10 ユーシービー バイオファルマ エスアールエル がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト
WO2020106461A2 (en) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anti-mertk antibodies and methods of use thereof
EP4061852A4 (en) * 2019-11-21 2024-03-13 Unity Biotechnology ANTIBODIES AGAINST TIE-2 AND METHODS OF USE
EP4232475A1 (en) * 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
US20240294622A1 (en) * 2021-01-18 2024-09-05 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
EP4511395A1 (en) * 2022-04-20 2025-02-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑
CN115786495A (zh) * 2022-10-24 2023-03-14 杭州市第七人民医院 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途
WO2024213066A1 (en) * 2023-04-13 2024-10-17 Suzhou Transcenta Therapeutics Co., Ltd. Combination therapies involving grem1 antagonists for treatment of cancer
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
AU6267098A (en) 1997-02-05 1998-08-25 Regents Of The University Of California, The Morphogenic proteins
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RU2336902C2 (ru) 2001-10-31 2008-10-27 Алькон, Инк. Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы
EP1777519A1 (en) 2001-10-31 2007-04-25 Alcon, Inc. Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
JP2008531525A (ja) 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド製剤を安定化する化合物
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2007124486A2 (en) 2006-04-21 2007-11-01 Childrens Hospital Los Angeles Bmp4 inhibitors
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
JP6339063B2 (ja) * 2012-03-15 2018-06-06 エスエヌユー アールアンドディービー ファウンデーション グレムリン−１に対する抗体
MX369574B (es) 2013-03-14 2019-11-13 Regeneron Pharma Anticuerpos humanos contra grem1.

Also Published As

Publication number Publication date
CN105189548A (zh) 2015-12-23
BR112015021979A2 (pt) 2017-08-29
SG10201707518YA (en) 2017-10-30
SG11201506459PA (en) 2015-09-29
CA2904644A1 (en) 2014-10-02
IL240769A0 (en) 2015-10-29
US10377817B2 (en) 2019-08-13
JP6581075B2 (ja) 2019-09-25
EP2970448A1 (en) 2016-01-20
HK1220469A1 (zh) 2017-05-05
US20160024195A1 (en) 2016-01-28
US20230192831A1 (en) 2023-06-22
JP2019151654A (ja) 2019-09-12
MX2015011616A (es) 2015-12-17
ZA201506113B (en) 2016-07-27
CA2904644C (en) 2022-09-20
PH12015501865A1 (en) 2015-12-07
MX369574B (es) 2019-11-13
WO2014159010A1 (en) 2014-10-02
EP2970448B1 (en) 2021-11-03
KR20150129718A (ko) 2015-11-20
AU2014241442B2 (en) 2018-11-15
US11634480B2 (en) 2023-04-25
ES2898620T3 (es) 2022-03-08
US20200157194A1 (en) 2020-05-21
AU2014241442A1 (en) 2015-10-15
EA201591762A1 (ru) 2015-12-30
JP2016519650A (ja) 2016-07-07

Similar Documents

Publication Publication Date Title
CL2015002603A1 (es) Anticuerpos humanos contragrem1.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
UY36032A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
PL3303632T3 (pl) Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
UY35967A (es) Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas
CL2018000429A1 (es) Moduladores de la expresión de kras
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CR20160347A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX392779B (es) Anticuerpos anti-cd27
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
GT201600050A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
MX2018006613A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.